Kevin Trapp ’88 has been named Chief Commercial Officer of DBV Technologies, a clinical-stage biopharmaceutical company.  . As part of the Company’s ongoing transformation into a commercial organization, he joins DBV after 27 years of driving portfolio growth through building leading brands at Bristol-Myers Squibb.  Mr. Briggs will be responsible for all worldwide commercial functions at DBV, including the potential launch of the Company’s lead product candidate, Viaskin Peanut, in 2019.